Neoadjuvant nivolumab plus chemotherapy in resectable non‐small‐cell lung cancer in Japanese patients from <scp>CheckMate</scp> 816Tetsuya Mitsudomi, Fumihiro Tanaka, Keisuke Tomii et al.|Cancer Science|2023Cited by 27
Adjuvant gefitinib versus cisplatin/vinorelbine in Japanese patients with completely resected, EGFR-mutated, stage II-III non-small cell lung cancer (IMPACT, WJOG6410L): A randomized phase 3 trial.Hirohito Tada, Tetsuya Mitsudomi, Takeharu Yamanaka et al.|Journal of Clinical Oncology|2021Cited by 24
Longitudinal recurrence risk of adjuvant cytotoxic chemotherapy and gefitnib in resected lung cancer: A combined analysis of phase III studiesHiroaki Akamatsu, Tetsuya Mitsudomi, Tomomi Nishikawa et al.|Lung Cancer|2025Cited by 2